Arcus Biosciences Inc
RCUS9.087USD
-0.073-0.79%
交易中 （美东）报价延迟15分钟
962.33M总市值
亏损市盈率 TTM
关于 Arcus Biosciences Inc 公司
Arcus Biosciences, Inc. 是一家临床阶段生物制药公司，致力于为癌症患者开发差异化分子和联合疗法。该公司涉及一系列研究产品，这些产品正处于临床开发阶段，其先进分子是一种针对肺癌和胃肠道癌症的抗 TIGIT 抗体。该公司有大约七个临床项目，重点关注靶点，包括 TIGIT、PD-1、腺苷 A2a 和 A2b 受体、CD73、CD39、HIF-2a 和 AXL。该公司正在共同开发四种研究产品，包括 zimberelimab（Arcuss 抗 PD-1 分子）、domvanalimab（Arcuss 抗 TIGIT 抗体）、etrumadenant（Arcuss 腺苷受体拮抗剂）和 quemliclustat（Arcuss CD73 抑制剂）。该公司正致力于开展 domvanalimab 与抗 PD-1 抗体 zimberelimab 联合治疗的 II 期和 III 期开发计划，用于治疗肺癌和胃肠癌等多种疾病。
公司简介
公司代码RCUS
公司名称Arcus Biosciences Inc
上市日期Mar 15, 2018
CEODr. Terry J. Rosen, Ph.D.
员工数量627
证券类型Ordinary Share
年结日Mar 15
公司地址3928 Point Eden Way
城市HAYWARD
上市交易所NYSE Consolidated
国家United States of America
邮编94545-3719
电话15106946200
网址https://arcusbio.com/
公司代码RCUS
上市日期Mar 15, 2018
CEODr. Terry J. Rosen, Ph.D.
公司高管
名称
名称/职务
职务
持股
持股变动
Dr. Juan Carlos Jaen, Ph.D.
Dr. Juan Carlos Jaen, Ph.D.
President, Co-Founder
President, Co-Founder
1.44M
-0.15%
Dr. Yasunori Kaneko, M.D.
Dr. Yasunori Kaneko, M.D.
Lead Independent Director
Lead Independent Director
943.86K
+1.43%
Dr. David L. Lacey, M.D.
Dr. David L. Lacey, M.D.
Independent Director
Independent Director
62.55K
+27.00%
Dr. Antoni Ribas, M.D., Ph.D.
Dr. Antoni Ribas, M.D., Ph.D.
Independent Director
Independent Director
43.80K
+43.60%
Mr. Patrick Machado, J.D.
Mr. Patrick Machado, J.D.
Independent Director
Independent Director
30.20K
+78.70%
Mrs. Nicole Lambert
Mrs. Nicole Lambert
Independent Director
Independent Director
28.90K
+85.26%
Dr. Andrew Perlman, M.D., Ph.D.
Dr. Andrew Perlman, M.D., Ph.D.
Independent Director
Independent Director
--
--
Mr. Richard Markus, M.D., Ph.D.
Mr. Richard Markus, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
--
--
Ms. Kathryn E. Falberg
Ms. Kathryn E. Falberg
Independent Director
Independent Director
--
--
Ms. Jennifer A. Jarrett
Ms. Jennifer A. Jarrett
Chief Operating Officer
Chief Operating Officer
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Dr. Juan Carlos Jaen, Ph.D.
Dr. Juan Carlos Jaen, Ph.D.
President, Co-Founder
President, Co-Founder
1.44M
-0.15%
Dr. Yasunori Kaneko, M.D.
Dr. Yasunori Kaneko, M.D.
Lead Independent Director
Lead Independent Director
943.86K
+1.43%
Dr. David L. Lacey, M.D.
Dr. David L. Lacey, M.D.
Independent Director
Independent Director
62.55K
+27.00%
Dr. Antoni Ribas, M.D., Ph.D.
Dr. Antoni Ribas, M.D., Ph.D.
Independent Director
Independent Director
43.80K
+43.60%
Mr. Patrick Machado, J.D.
Mr. Patrick Machado, J.D.
Independent Director
Independent Director
30.20K
+78.70%
Mrs. Nicole Lambert
Mrs. Nicole Lambert
Independent Director
Independent Director
28.90K
+85.26%
收入明细
单位: USD更新时间: 7月6日 周日
单位: USD更新时间: 7月6日 周日
FY2025Q1
FY2024
FY2023
FY2022
FY2021
FY2020
业务USD
名称
营收
占比
License and development services revenue
20.00M
71.43%
Collaboration revenue
8.00M
28.57%
暂无数据
业务
地区
业务USD
名称
营收
占比
License and development services revenue
20.00M
71.43%
Collaboration revenue
8.00M
28.57%
股东统计
更新时间: 6月8日 周日
更新时间: 6月8日 周日
持股股东
股东类型
持股股东
持股股东
占比
Gilead Sciences Inc
29.68%
BlackRock Institutional Trust Company, N.A.
9.14%
The Vanguard Group, Inc.
6.30%
Woodline Partners LP
4.84%
Fidelity Management & Research Company LLC
3.90%
Other
46.14%
持股股东
持股股东
占比
Gilead Sciences Inc
29.68%
BlackRock Institutional Trust Company, N.A.
9.14%
The Vanguard Group, Inc.
6.30%
Woodline Partners LP
4.84%
Fidelity Management & Research Company LLC
3.90%
Other
46.14%
股东类型
持股股东
占比
Corporation
29.68%
Investment Advisor
27.66%
Hedge Fund
17.50%
Investment Advisor/Hedge Fund
12.68%
Individual Investor
5.36%
Venture Capital
2.82%
Research Firm
1.88%
Pension Fund
0.62%
Bank and Trust
0.29%
Other
1.52%
机构持股
更新时间: 7月1日 周二
更新时间: 7月1日 周二
报告期
机构数
持股数
持股占比
持股变动
2025Q2
438
104.36M
98.58%
+5.92M
2025Q1
461
106.23M
100.41%
+7.59M
2024Q4
458
92.45M
92.67%
-8.14M
2024Q3
459
92.17M
107.84%
+6.16M
2024Q2
456
90.82M
107.03%
+3.48M
2024Q1
456
91.60M
108.07%
-2.14M
2023Q4
455
76.21M
102.30%
-15.07M
2023Q3
450
76.35M
103.06%
-17.88M
2023Q2
441
78.29M
107.10%
-16.66M
2023Q1
448
78.22M
107.14%
-13.36M
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
Gilead Sciences Inc
31.42M
29.68%
--
--
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
9.68M
9.14%
+1.14M
+13.37%
Mar 31, 2025
The Vanguard Group, Inc.
6.68M
6.3%
+1.30M
+24.15%
Mar 31, 2025
Woodline Partners LP
5.13M
4.84%
+1.60M
+45.50%
Mar 31, 2025
Fidelity Management & Research Company LLC
4.12M
3.9%
+404.71K
+10.88%
Mar 31, 2025
State Street Global Advisors (US)
3.70M
3.49%
+702.75K
+23.47%
Mar 31, 2025
Point72 Asset Management, L.P.
2.87M
2.71%
+870.82K
+43.62%
Mar 31, 2025
Rosen Terry Jay
2.57M
2.43%
-472.90K
-15.53%
Mar 01, 2025
Suvretta Capital Management, LLC
2.56M
2.42%
+1.98M
+344.48%
Mar 31, 2025
Dimensional Fund Advisors, L.P.
1.72M
1.63%
+19.78K
+1.16%
Mar 31, 2025
查看更多
持股ETF
更新时间: 8月2日 周六
更新时间: 8月2日 周六
机构名称
占比
iShares Genomics Immunology and Healthcare ETF
1.2%
Virtus LifeSci Biotech Clinical Trials ETF
0.78%
ALPS Medical Breakthroughs ETF
0.58%
Tema Oncology ETF
0.5%
Invesco S&P SmallCap Health Care ETF
0.39%
Invesco S&P SmallCap 600 Pure Growth ETF
0.31%
SPDR S&P Biotech ETF
0.2%
Direxion Daily S&P Biotech Bull 3X Shares
0.12%
Vanguard S&P Small-Cap 600 Growth Index Fund
0.08%
iShares S&P Small-Cap 600 Growth ETF
0.08%
查看更多
iShares Genomics Immunology and Healthcare ETF
占比1.2%
Virtus LifeSci Biotech Clinical Trials ETF
占比0.78%
ALPS Medical Breakthroughs ETF
占比0.58%
Tema Oncology ETF
占比0.5%
Invesco S&P SmallCap Health Care ETF
占比0.39%
Invesco S&P SmallCap 600 Pure Growth ETF
占比0.31%
SPDR S&P Biotech ETF
占比0.2%
Direxion Daily S&P Biotech Bull 3X Shares
占比0.12%
Vanguard S&P Small-Cap 600 Growth Index Fund
占比0.08%
iShares S&P Small-Cap 600 Growth ETF
占比0.08%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据
